ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023
Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06440304 (Therapeutic Strategies for Carbapenem-Resistant Acinetobacter Baumannii Infections), which is not on this map. Cited by 86 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Therapeutic Strategies for Carbapenem-Resistant Acinetobacter Baumannii Infections: Study Protocol
Who cites it
86 citing papers in PubMed, 3 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2026Pooled it
- Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis.BMC infectious diseases · 2024Pooled it
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- Genotypic and Phenotypic Resistance Profiles of InvasiveMicroorganisms · 2026Article
- A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Sulbactam-Durlobactam for Carbapenem-ResistantPathogens (Basel, Switzerland) · 2026Review
- Sulbactam-Durlobactam in the Treatment of Bloodstream Infection Due to Carbapenem-ResistantJournal of clinical medicine · 2026Review
- Ampicillin/Sulbactam in Combination with Ceftazidime/Avibactam Against Metallo-β-Lactamase-Producing Carbapenem-Resistant Acinetobacter baumannii: A Genomics-Informed Mechanism-based model.The Journal of infectious diseases · 2026Article
- Risk factors for carbapenem-resistantJAC-antimicrobial resistance · 2026Article
- High-Dose Minocycline Improves Outcomes in Acinetobacter baumannii Group Pneumonia: A Propensity-Weighted Cohort Study with MIC-Based Insights for Breakpoint Revision.Infectious diseases and therapy · 2026Article
- A Review ofInternational journal of microbiology · 2026Review
- Thoracic Extension of an Odontogenic Deep Neck Space Infection: A Case of Carbapenem-ResistantInfection and drug resistance · 2026Article
- Therapeutic challenges and emerging strategies against carbapenem-resistantCurrent research in microbial sciences · 2026Review
- Molecular analysis of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Real-World Evidence and Multidrug Resistant Infections: How Can We Leverage RWE to Improve Patient Outcome with the Novel Beta-Lactam and Beta-Lactam/Beta-Lactamase Inhibitor Combinations.Infection and drug resistance · 2026Review
- Case Report: Successful salvage therapy with sulbactam-durlobactam combined with meropenem for carbapenem-resistant Acinetobacter baumannii bloodstream infection in a child after failure of allogeneic hematopoietic stem cell transplantation.Frontiers in pediatrics · 2026Article
- Anti-Infective-Associated AKI: A Narrative Review of the Epidemiology, Mechanisms, Risk Factors, Biomarkers, Clinical Course, Monitoring, Prevention, and Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2025Review
- Outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections in intensive care units and prognostic effect of different antimicrobial regimens.Annals of intensive care · 2025Article
- Demystify Carbapenem-resistant Acinetobacter baumannii Pneumonia Burden: 2-Year Cohort Study.Annals of African medicine · 2025Article
- Turning the Tide Against Carbapenem-resistantOpen forum infectious diseases · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) is one of the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant threats, none of the available therapies have been shown to consistently reduce mortality or improve patient outcomes in clinical trials. Antibiotic combination therapy is routinely used in clinical practice; however, the preferred combination has not been defined. This narrative review focuses on evidence-based solutions for the treatment of invasive CRAB infections. We dissect the promise and perils of traditional agents used in combination, such as colistin, sulbactam, and the tetracyclines, and offer clinical pearls based on our interpretation of the available data. Next, we investigate the merits of newly developed β-lactam agents like cefiderocol and sulbactam-durlobactam, which have demonstrated contrasting results in recent randomized clinical trials. The review concludes with the authors' perspective on the evolving treatment landscape for CRAB infections, which is complicated by limited clinical data, imperfect treatment options, and a need for future clinical trials. We propose that effective treatment for CRAB infections requires a personalized approach that incorporates host factors, the site of infection, pharmacokinetic-pharmacodynamic principles, local molecular epidemiology of CRAB isolates, and careful interpretation of antibiotic susceptibility testing results. In most clinical scenarios, a dose-optimized, sulbactam-based regimen is recommended with the addition of at least one other in vitro active agent. Should sulbactam-durlobactam receive regulatory approval, recommendations will need to be re-evaluated with the most recent evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.